Decision Impact Trial of KidneyIntelX
Active, not recruiting · NCT04791358
Conditions: Diabetic Kidney Disease
At a glance
- Research payments reported, 2025
- $35,020
- U.S. investigators named
- 6
- Sites paid
- 5
- Planned or actual enrollment
- 1,500
About the trial
- Sponsor
- Renalytix AI, Inc.
- Tested
- KidneyIntelX (diagnostic_test)
- Dates
- Started 2021-11-01; completion 2026-12-01
- Results posted
- Not yet
The current trial is designed to evaluate how the results of KidneyIntelX test impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
From ClinicalTrials.gov, last updated 2026-08-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Renalytix Ai, Inc. reported $35,020 in research payments for this study in 2025 (12 payments).
Products named: Kidneyintelx Blood Collection Convenience Kit
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Adetutu B. Adetona, M.D. Family Medicine · Troy, NY
- Tahir Effendi, M.D. Internal Medicine · Watervliet, NY
- William J. Feeney, MD Internal Medicine · Latham, NY
- Joseph P. Fusella, D.O. Family Medicine · Schenectady, NY
- Gerald J. Hausler, DO Family Medicine · Latham, NY
- Louis C. Ianniello, M.D. Family Medicine · Schenectady, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Community Care Physicians PLLC $13,260
- American Horizon Medical PLLC $10,880
- Feeney Medical Group $7,140
- Center for Family Practice $2,040
- Lansingburgh Family Practice PC $1,700
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.